Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | RECQL | P46063 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CKS1B | P61024 | 1/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434169 | 0.94 | HPGD (0.58) | HPGDRECQLMAPK1CKS1BSKP2 | |
| SCHEMBL22441306 | 0.82 | HPGD (0.65) | HPGDRECQLMAPK1RAB9AEPHX2 | |
| SCHEMBL2388952 | 0.80 | EPHX2 (0.58) | EPHX2CA2MEN1KMT2A | |
| SCHEMBL2386670 | 0.76 | PPARG (0.56) | HPGDRECQLMAPK1EPHX2ALDH1A1 | |
| SCHEMBL28896490 | 0.76 | CNR2 (0.51) | HPGDRECQLMAPK1EPHX2ALDH1A1 | |
| SCHEMBL9804183 | 0.76 | HPGD (0.63) | HPGDRECQLRAB9AALDH1A1NPC1 | |
| SCHEMBL3083718 | 0.76 | HPGD (0.63) | HPGDRECQLRAB9AALDH1A1NPC1 | |
| SCHEMBL21310015 | 0.75 | KMT2A (0.56) | HPGDRECQLMAPK1RAB9AEPHX2 | |
| SCHEMBL2388248 | 0.75 | ALDH1A1 (0.50) | HPGDRECQLMAPK1EPHX2ALDH1A1 | |
| SCHEMBL1421044 | 0.75 | HDAC6 (0.64) | HPGDRECQLMAPK1RAB9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2957558-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| EP-2757105-A1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Abbvie Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2550258-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8343967-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120214796-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2012-08-23 | — | — | US | disclosed |
| US-8188077-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2011119345-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214796-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HPGD 1466/4885RECQL 3570/4885MAPK1 2721/4885 |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HPGD 1466/4885RECQL 3570/4885MAPK1 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.